Last reviewed · How we verify
Immediate Release Methylphenidate
At a glance
| Generic name | Immediate Release Methylphenidate |
|---|---|
| Also known as | Generic Methylphenidate, IR MPH, Ritalin |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Methylphenidate and Response to Alcohol Cues Pilot Study (EARLY_PHASE1)
- Methylphenidate and Response to Alcohol Cues (PHASE2)
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders (PHASE3)
- The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD) (NA)
- Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children (PHASE4)
- The Effects of Methylphenidate and Non-invasive Brain Stimulation on Inhibitory Control in Children With ADHD (NA)
- The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |